PARP inhibitors have shown significant efficacy in extending progression-free survival in patients with BRCA-mutated cancers. Clinical trials have demonstrated that these drugs can slow disease progression and, in some cases, even achieve partial or complete remission. Their effectiveness is particularly notable in patients who have previously undergone multiple lines of therapy.
